Huadong Medicine
Huadong Medicine
Huadong Medicine is a comprehensive pharmaceuticals company.
Huadong Medicine, founded in March 1993 and headquartered in Hangzhou, is a comprehensive manufacturer and distributor of various types of antibiotics, proprietary Chinese medicines, and synthetic drugs. The founder is Lu Liang. Listed on the Shenzhen Stock Exchange on January 27, 2020, the company's major shareholders are China Grand Enterprises and Hangzhou Huadong Medicine. The direct and indirect competitors of Huadong Medicine include Hengrui Medicine, Humanwell Healthcare, Kelun Pharmaceutical.
- All
- News
- Analysis
- Research
Briefing May 27, 2021 02:02 AM
· Healthcare
Alibaba Health Information publishes rather poor annual figures
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing May 13, 2021 06:43 PM
· Healthcare
HealthTech Miaoshou Doctor (Tencent Investment) ahead of IPO
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Industrials, Financials, AutomotiveTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Industrials, Financials, AutomotiveLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Feb 07, 2021 06:55 PM
· Healthcare
Deyi sunshine completed tens of millions of Yuan round B financing
Briefing Feb 03, 2021 09:42 AM
· Healthcare
Jingtai technology has signed cooperation with new Geyuan to develop targeted drugs with AI and single cell sequencing as new tumor targets
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Briefing Dec 23, 2020 11:21 AM
· Healthcare
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Briefing Dec 18, 2020 05:51 PM
· Healthcare
The third indication of the anti fibrotic treatment of bringer Ingelheim was approved in China
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Healthcare
WIM2020: Insights on the Post-pandemic Outlook for the Healthcare Industry
The curtain came down on Dec 10 on the 'Healthtech Industry and COVID-19 Pandemic' Chapter at WIM 2020. Healthtech entrepreneurs and investors gathered to share insights on the outlook for the healthcare industry, covering topics like vaccination, AI healthcare, intelligent hardware, medical appliances and IVD.
Jan 07, 2021 02:10 PM
Healthcare, Real Estate, Automotive
WIM2020: Uniting the World through Technology and Innovation
On December 9-12, EqualOcean held the World Innovators Meet (WIM) 2020. This year, the event's main topic was 'Technology and Innovation Connect the World.' WIM2020 gathered innovators from Asia, Africa, Europe and North America to share their knowledge and key achievements, promoting the concept of 'Tech for Equal.'
Dec 17, 2020 07:53 PM
Briefing Nov 19, 2020 09:47 AM
· Healthcare
Lukang Pharmaceutical holding subsidiary ambroxol hydrochloride injection obtained drug registration certificate
Briefing Nov 17, 2020 08:04 PM
· Healthcare
Plan to raise $4 billion! Jingdong health runs IPO
Briefing Nov 11, 2020 10:42 AM
· Healthcare
Drug Innovator Asieris Nabs CNY 700 Million Series D
Briefing Sep 28, 2020 08:25 PM
· Healthcare
Chinese Biotech Zai Laboratory Lands on HKEX after 3 Years' Listing on Nasdaq
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
- Haier Balances Smart Home Demand at Home and Overseas Trends
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.